Cargando…

Targeted Prodrug-Based Self-Assembled Nanoparticles for Cancer Therapy

BACKGROUND: Targeted prodrug has various applications as drug formulation for tumor therapy. Therefore, amphoteric small-molecule prodrug combined with nanoscale characteristics for the self-assembly of the nano-drug delivery system (DDS) is a highly interesting research topic. METHODS AND RESULTS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Weiwei, Fan, Junting, Zhu, Guang, Wang, Jing, Qian, Yumei, Li, Hongxia, Ju, Jianming, Shan, Lingling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187935/
https://www.ncbi.nlm.nih.gov/pubmed/32425524
http://dx.doi.org/10.2147/IJN.S247443
_version_ 1783527248822796288
author Wang, Weiwei
Fan, Junting
Zhu, Guang
Wang, Jing
Qian, Yumei
Li, Hongxia
Ju, Jianming
Shan, Lingling
author_facet Wang, Weiwei
Fan, Junting
Zhu, Guang
Wang, Jing
Qian, Yumei
Li, Hongxia
Ju, Jianming
Shan, Lingling
author_sort Wang, Weiwei
collection PubMed
description BACKGROUND: Targeted prodrug has various applications as drug formulation for tumor therapy. Therefore, amphoteric small-molecule prodrug combined with nanoscale characteristics for the self-assembly of the nano-drug delivery system (DDS) is a highly interesting research topic. METHODS AND RESULTS: In this study, we developed a prodrug self-assembled nanoplatform, 2-glucosamine-fluorescein-5(6)-isothiocyanate-glutamic acid-paclitaxel (2DA-FITC-PTX NPs) by integration of targeted small molecule and nano-DDS with regular structure and perfect targeting ability. 2-glucosamine (DA) and paclitaxel were conjugated as the targeted ligand and anti-tumor chemotherapy drug by amino acid group. 2-DA molecular structure can enhance the targeting ability of prodrug-based 2DA-FITC-PTX NPs and prolong retention time, thereby reducing the toxicity of normal cell/tissue. The fluorescent dye FITC or near-infrared fluorescent dye ICG in prodrug-based DDS was attractive for in vivo optical imaging to study the behavior of 2DA-FITC-PTX NPs. In vitro and in vivo results proved that 2DA-FITC-PTX NPs exhibited excellent targeting ability, anticancer activity, and weak side effects. CONCLUSION: This work demonstrates a new combination of nanomaterials for chemotherapy and may promote prodrug-based DDS clinical applications in the future.
format Online
Article
Text
id pubmed-7187935
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-71879352020-05-18 Targeted Prodrug-Based Self-Assembled Nanoparticles for Cancer Therapy Wang, Weiwei Fan, Junting Zhu, Guang Wang, Jing Qian, Yumei Li, Hongxia Ju, Jianming Shan, Lingling Int J Nanomedicine Original Research BACKGROUND: Targeted prodrug has various applications as drug formulation for tumor therapy. Therefore, amphoteric small-molecule prodrug combined with nanoscale characteristics for the self-assembly of the nano-drug delivery system (DDS) is a highly interesting research topic. METHODS AND RESULTS: In this study, we developed a prodrug self-assembled nanoplatform, 2-glucosamine-fluorescein-5(6)-isothiocyanate-glutamic acid-paclitaxel (2DA-FITC-PTX NPs) by integration of targeted small molecule and nano-DDS with regular structure and perfect targeting ability. 2-glucosamine (DA) and paclitaxel were conjugated as the targeted ligand and anti-tumor chemotherapy drug by amino acid group. 2-DA molecular structure can enhance the targeting ability of prodrug-based 2DA-FITC-PTX NPs and prolong retention time, thereby reducing the toxicity of normal cell/tissue. The fluorescent dye FITC or near-infrared fluorescent dye ICG in prodrug-based DDS was attractive for in vivo optical imaging to study the behavior of 2DA-FITC-PTX NPs. In vitro and in vivo results proved that 2DA-FITC-PTX NPs exhibited excellent targeting ability, anticancer activity, and weak side effects. CONCLUSION: This work demonstrates a new combination of nanomaterials for chemotherapy and may promote prodrug-based DDS clinical applications in the future. Dove 2020-04-24 /pmc/articles/PMC7187935/ /pubmed/32425524 http://dx.doi.org/10.2147/IJN.S247443 Text en © 2020 Wang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Wang, Weiwei
Fan, Junting
Zhu, Guang
Wang, Jing
Qian, Yumei
Li, Hongxia
Ju, Jianming
Shan, Lingling
Targeted Prodrug-Based Self-Assembled Nanoparticles for Cancer Therapy
title Targeted Prodrug-Based Self-Assembled Nanoparticles for Cancer Therapy
title_full Targeted Prodrug-Based Self-Assembled Nanoparticles for Cancer Therapy
title_fullStr Targeted Prodrug-Based Self-Assembled Nanoparticles for Cancer Therapy
title_full_unstemmed Targeted Prodrug-Based Self-Assembled Nanoparticles for Cancer Therapy
title_short Targeted Prodrug-Based Self-Assembled Nanoparticles for Cancer Therapy
title_sort targeted prodrug-based self-assembled nanoparticles for cancer therapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187935/
https://www.ncbi.nlm.nih.gov/pubmed/32425524
http://dx.doi.org/10.2147/IJN.S247443
work_keys_str_mv AT wangweiwei targetedprodrugbasedselfassemblednanoparticlesforcancertherapy
AT fanjunting targetedprodrugbasedselfassemblednanoparticlesforcancertherapy
AT zhuguang targetedprodrugbasedselfassemblednanoparticlesforcancertherapy
AT wangjing targetedprodrugbasedselfassemblednanoparticlesforcancertherapy
AT qianyumei targetedprodrugbasedselfassemblednanoparticlesforcancertherapy
AT lihongxia targetedprodrugbasedselfassemblednanoparticlesforcancertherapy
AT jujianming targetedprodrugbasedselfassemblednanoparticlesforcancertherapy
AT shanlingling targetedprodrugbasedselfassemblednanoparticlesforcancertherapy